VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...

Given the complexity of alternative-protein manufacturing, many biotech companies are exploring how to reduce costs with AI technologies, process improvements and novel uses for waste streams from ...

Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system. “With ...

IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, advances toward first-in-human clinical trials, with an Investigational New Drug (IND) submission ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...